|Bid||0.00 x 1000|
|Ask||11.50 x 2200|
|Day's Range||9.72 - 10.07|
|52 Week Range||9.01 - 26.26|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.54|
Santen Pharmaceutical Co., Ltd. ("Santen") and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, "Aerie") announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa® and Rocklatan® in Japan, along with rights for several other Asian countries.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its third quarter 2020 financial results will be released after the market closes on Thursday, November 5, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So spare a thought for...